Browse > Article

Review of Radionuclide Treatment for Neuroendocrine Tumors  

Jeong, Hwan-Jeong (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Publication Information
Nuclear Medicine and Molecular Imaging / v.40, no.2, 2006 , pp. 90-95 More about this Journal
Abstract
Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors that are able to uptake neuroamine and/or specific receptors, such as somatostatin receptors, which can play important roles of the localization and treatment of these tumors. When considering therapy with radionuclides, the best radioligand should be carefully investigated. $^{131}I$-MIBG and beta-particle emitter labeled somatostatin analogs are well established radionuclide therapy modalities for NETs. $^{111}In,\;^{90}Y\;and\;^{177}Lu$ radiolabeled somatostatin analogues have been used for treatment of NETs. Further, radionuclide therapy modalities, for example, radioimmunotherapy, radiolabeled peptides such as minigastrin are currently under development and in different phases of clinical investigation. for all radionuclides used for therapy, long-term and survival statistics are not yet available and only partial tumour responses have been obtained using $^{131}I$-MIBG and $^{111}In$-octreotide. Experimental results using $^{90}Y$-DOTA-lanreotide as well as $^{90}Y-DOTA-D-Phe1-Tyr^3-octreotide$ and/or $^{177}Lu-DOTA-Tyr^3-octreotate$ have indicated the possible clinical potential of radionuclides receptor-targeted radiotherapy it may be hoped that the efficacy of radionuclide therapy will be improved by co-administration of chemotherapeutic drugs whose antitumoral properties may be synergistic with that of irradiation.
Keywords
neuroendocrine tumor; MIBG; somatostatin; radionuclide therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine ($^{131}$I-MIBG): a comprehensive review of 116 reported patients. J Endocrinoll Invest 1997;20:648-58   DOI
2 Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98   DOI   ScienceOn
3 Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-9
4 Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995;36:623-7
5 Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with $^{111}$In-DTPA-D-Phe1- and $^{123}$I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31   DOI
6 Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated $^{90}$Y labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004;58:1215-27   DOI   ScienceOn
7 Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, et al. Characterization of $^{123}$I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 2001;91:789-96   DOI   ScienceOn
8 Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of $^{111}$In-DOTA-Tyr3-octreotide and $^{111}$In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-7
9 de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-92
10 Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242-4
11 Troncone L, Rufini V. $^{131}$I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997;17:1823-31
12 Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol 2002;29:152-9   DOI   ScienceOn
13 Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic andradiotherapeutic use. Eur J Nucl Med 2000;27:273-82   DOI
14 Chatal JF, Le Bodic MF, Kraeber-Bodere F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J Surg 2000;24:1285-9   DOI   ScienceOn
15 Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000;44:22-41
16 Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-8
17 Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60
18 Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobezylguanidine (MIBG). Nucl Med Comm 1992;13:513-21   DOI
19 Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur J Pharmacol 1998;345:103-10   DOI   ScienceOn
20 Caplin ME, Buscombe JR, Hilson AJ. Carcinoid tumour. Lancet 1998;352:799-805   DOI   ScienceOn
21 Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol 2001;12(Suppl 2); S41-S45
22 Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437-9   DOI   ScienceOn
23 Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002;62:6124-31
24 Khafagi FA, Shapiro B, Fig LM. Labetolol reduces $^{131}$I MIBG uptake by pheochromocytoma and normal tissue. J Nucl Med 1989;30:481-9
25 Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, et al. In vitro and in vivo studies of three radiolabelled somatostatin analogues: $^{123}$I-octreotide (OCT), $^{123}$I-Tyr-3-OCT and $^{111}$In-DTPA- D-Phe-1-OCT. Eur J Nucl Med 1996;23:1388-99   DOI
26 Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann. ncol 2001;12(Suppl): S51-S61
27 de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [$^{177}$Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33   DOI   ScienceOn
28 Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003;14:1274-7   DOI   ScienceOn
29 de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nuc Med Mol Imaging 2003;30:463-469   DOI   ScienceOn
30 Chatal JF, Le Bodic MF, Kraeber-Bodere F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J. Surg 2000;24:1285-9   DOI   ScienceOn
31 Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, et al. Iodine-123-Vascular Endothelial Growth Factor-165 (123I-VEGF165): Biodistribution, Safety and Radiation Dosimetry in Patients with Pancreatic Carcinoma. Q J Nucl Med Mol Imaging 2004;48: 198-206
32 Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14   DOI
33 Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann NY Acad Sci 2004;1014:234-45   DOI   ScienceOn
34 Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000;44:3-12
35 Kwekkeboom DJ, Kooij PP, Bakker WH, van der Pluijm ME, Srinivasan A, Erion J, et al. Lu-177-DOTA-Tyr3-octreotate: comparison with In-111-DTPA-octreotide in patients. Eur J Nucl Med 2001;28:1319-25   DOI   ScienceOn
36 Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67   DOI
37 Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with ($^{131}$I-meta-iodobenzylguanidine ($^{131}$I mIBG). Clin Endocrinol 2001;55:47-60   DOI   ScienceOn
38 Treatment of metastatic pheochromocytoma and paraganglioma with $^{131}$I-meta-iodobenzylguanidine (MIBG). Endocrinologist 2003;13:1-13   DOI   ScienceOn
39 Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995-1008   DOI   ScienceOn
40 Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9   DOI   ScienceOn
41 Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344-55
42 Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using $^{131}$I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000;41:93-103
43 Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637-44